FASEB J. Avanti Polar Lipids
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH SEARCH RESULT
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF) Free
Right arrow 2 column PDF
Right arrow All Versions of this Article:
15/7/1300
00-0564fjev1    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sakiyama-Elbert, S. E.
Right arrow Articles by Hubbell, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakiyama-Elbert, S. E.
Right arrow Articles by Hubbell, J. A.
The FASEB Journal Express Article doi:10.1096/fj.00-0564fje
Published online March 20, 2001

Development of growth factor fusion proteins for cell-triggered drug delivery

Shelly E. Sakiyama-Elbert, Alyssa Panitch, and Jeffrey A. Hubbell

E-mail contact: hubbell{at}biomed.mat.ethz.ch

The goal of this research was to develop an approach to growth factor delivery that would allow the stable incorporation of growth factors within a cell in-growth matrix in a manner such that local enzymatic activity associated with tissue regeneration could trigger growth factor release. We investigated this approach in the context of peripheral nerve regeneration by designing modified beta-nerve growth factor (b-NGF) fusion proteins and testing their ability to promote neurite extension. Fibrin was selected as the cell in-growth matrix, and the transglutaminase activity of factor XIIIa was utilized to covalently incorporate b-NGF fusion proteins within fibrin matrices. Novel b-NGF fusion proteins, which contained an exogenous factor XIIIa substrate to allow incorporation into fibrin matrices, were expressed recombinantly. An intervening plasmin substrate domain was placed between the factor XIIIa substrate and the NGF domain to allow cell-mediated growth factor release in response to plasmin, which is generated by invading cells. Immobilized NGF fusion protein with an intervening functional plasmin cleavage sequence enhanced neurite extension from embryonic chick dorsal root ganglia by 50% relative to soluble native b-NGF and by 350% relative to the absence of NGF. These results suggest that this novel approach to growth factor delivery, in which the factor is delivered upon cellular demand, could enhance nerve regeneration and may be useful in tissue engineering.

Key words: Fibrin · nerve growth factor · protein delivery · tissue engineering




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
D. J. Geer, D. D. Swartz, and S. T. Andreadis
Biomimetic Delivery of Keratinocyte Growth Factor upon Cellular Demand for Accelerated Wound Healing in Vitro and in Vivo
Am. J. Pathol., December 1, 2005; 167(6): 1575 - 1586.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. C. Weber, H. Cai, M. Ehrbar, H. Kubota, G. Martiny-Baron, W. Weber, V. Djonov, E. Weber, A. S. Mallik, M. Fussenegger, et al.
Effects of Protein and Gene Transfer of the Angiopoietin-1 Fibrinogen-like Receptor-binding Domain on Endothelial and Vessel Organization
J. Biol. Chem., June 10, 2005; 280(23): 22445 - 22453.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Ehrbar, V. G. Djonov, C. Schnell, S. A. Tschanz, G. Martiny-Baron, U. Schenk, J. Wood, P. H. Burri, J. A. Hubbell, and A. H. Zisch
Cell-Demanded Liberation of VEGF121 From Fibrin Implants Induces Local and Controlled Blood Vessel Growth
Circ. Res., April 30, 2004; 94(8): 1124 - 1132.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH SEARCH RESULT
Copyright © 2001 by The Federation of American Societies for Experimental Biology.